🕒 Tuesday 14 April 2026 Tue, 14 Apr 2026

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Galilee Energy has completed the Zydeco-1 well design and directional plan, achieving around US$100,000 in cost savings and advancing steadily toward a Q2 2026 drilling start. The project targets Gulf Coast natural gas and condensate markets, supported by a newly appointed US Advisory Board.

Xref Limited has unveiled Xref.me, a pioneering platform that transforms recruitment by shifting to verified digital resumes at application, unlocking new pay-per-access revenue streams and expanding its enterprise SaaS funnel.

Vita Resources has completed a $100,000 capital raise via a placement featuring a novel partly paid share class designed specifically for mining companies. This new share structure defers calls until at least 2030, offering investors flexibility and the company a unique capital management tool.

Westpac Banking Corporation reports steady lending and deposit growth alongside stable margins despite geopolitical headwinds, while transaction costs from its RAMS mortgage portfolio sale weigh on first-half profits.

Cleanaway has trimmed its FY26 EBIT forecast to $460-$480 million, citing a $20 million hit from rising fuel and logistics costs linked to the Middle East war. The company leans on contractual fuel cost pass-throughs and strategic supply deals to cushion the blow.

Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.